Stock Financial Ratios, Dividends, Split History

TSX:BCB / Cott Corp financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)0.00
Enterprise Value ($M)1,076.40
Book Value ($M)1,263.80
Book Value / Share9.01
Price / Bookn/a
NCAV ($M)-1,260.60
NCAV / Share-8.99
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 140,081,348
Weighted Average Number Of Shares Outstanding Basic 139,078,000
Weighted Average Number Of Diluted Shares Outstanding 139,078,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.00
Return on Assets (ROA)0.00
Return on Equity (ROE)0.01
Balance Sheet (mrq) ($M)
Quick Ratio1.23
Current Ratio1.54
Income Statement (mra) ($M)
Sales Revenue Net2,269,700,000.00
Operating Income48.90
Net Income7.10
Earnings Per Share Basic-0.01
Earnings Per Share Diluted-0.01
Cash Flow Statement (mra) ($M)
Cash From Operations176.00
Cash from Investing-153.60
Cash from Financing176.00
Identifiers and Descriptors
Central Index Key (CIK)884713

Split History

Stock splits are used by Cott Corp to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

CANADA STOCKS-TSX edges higher, powered by gains in energy stocks

2018-06-01 reuters
June 1 (Reuters) - Canada’s main stock index edged higher on Friday as gains in shares of energy companies more than offset losses in the heavyweight financials index. (28-0)

Pass On New Age Beverages

2018-05-22 seekingalpha
Reasons for skepticism include a poor track record, bad incentives for management, questionable health benefits of products, and weak profitability. (6-3)

Pilgrim's Pride (PPC) to Report Q1 Earnings: What to Expect?

2018-05-09 zacks
Pilgrim's Pride Corporation (PPC - Free Report) is scheduled to report first-quarter 2018 results on Apr 10, after the market closes. The company reported better-than-expected results in three of the last four quarters, while lagging in one. Average earnings surprise was a positive 8.62%. Notably, in the last reported quarter, the company’s earnings of 58 cents per share surpassed the Zacks Consensus Estimate by 9. (8-0)

Cott (Canada) (COT) Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Welcome to Cott Corporation's First Quarter 2018 Earnings Conference Call. All participants are currently in listen-only mode. This call will end no later than 11:00 am Eastern time. This call is being webcast live on Cott's website at and will be available for a playback there until May 17, 2018. (3-0)

Dr Pepper's (DPS) Q1 Earnings Miss, Revenues Beat Estimates

2018-04-26 zacks
Dr Pepper Snapple Group Inc.’s (DPS - Free Report) first-quarter 2018 earnings missed the Zacks Consensus Estimate while revenues beat the same. Revenues benefited from a growth in sales volumes, favorable product and package mix, segment mix as well as foreign currency translation. Recently, the company announced its acquisition agreement with the well-known coffee maker Keurig Green Mountain, Inc. (4-0)